Paper35948006
Discovery of compounds that reactivate p53 mutants in vitro and in vivo.
Durairaj G and 21 others. Cell Chem Biol, 2022. Cited by 30 papers, by iCite.
Cite this record
ConductScience Library. Discovery of compounds that reactivate p53 mutants in vitro and in vivo. Papers, record 35948006. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35948006
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoplasms | Major topic |
| Tumor Suppressor Protein p53 | Major topic |
| Cell Line, Tumor | |
| Chromatin | |
| DNA | |
| Humans | |
| Mutation | |
| Protein Domains |
Source PubMed
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R21 NS063874 | NINDS NIH HHS | United States | R21NS063874 | PubMed and NIH | NIH RePORTER |
| R21 CA267495 | NCI NIH HHS | United States | R21CA267495 | PubMed and NIH | NIH RePORTER |
| R01 GM132826 | NIGMS NIH HHS | United States | R01GM132826 | PubMed and NIH | NIH RePORTER |
| R01 CA112560 | NCI NIH HHS | United States | R01CA112560 | PubMed and NIH | NIH RePORTER |
| UL1 TR001414 | NCATS NIH HHS | United States | UL1TR001414 | PubMed and NIH | NIH RePORTER |
| P30 CA062203 | NCI NIH HHS | United States | P30CA062203 | PubMed and NIH | NIH RePORTER |
References44
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23161690 | The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. | Nucleic Acids Res | 2013 | https://conductscience.org/library/papers/23161690 | PubMed |
| 2 | 17251932 | Restoration of p53 function leads to tumour regression in vivo. | Nature | 2007 | https://conductscience.org/library/papers/17251932 | PubMed |
| 3 | 17538933 | Restoration of p53 function: a new therapeutic strategy to induce tumor regression? | Hepatology | 2007 | https://conductscience.org/library/papers/17538933 | PubMed |
| 4 | 20581117 | All-codon scanning identifies p53 cancer rescue mutations. | Nucleic Acids Res | 2010 | https://conductscience.org/library/papers/20581117 | PubMed |
| 5 | 25075903 | Improved vectors and genome-wide libraries for CRISPR screening. | Nat Methods | 2014 | https://conductscience.org/library/papers/25075903 | PubMed |
| 6 | 24157548 | Genome engineering using the CRISPR-Cas9 system. | Nat Protoc | 2013 | https://conductscience.org/library/papers/24157548 | PubMed |
| 7 | 17182091 | Modeling the therapeutic efficacy of p53 restoration in tumors. | Cell | 2006 | https://conductscience.org/library/papers/17182091 | PubMed |
| 8 | 30157040 | RITA induces apoptosis in p53-null K562 leukemia cells by inhibiting STAT5, Akt, and NF-κB signaling pathways. | Anticancer Drugs | 2018 | https://conductscience.org/library/papers/30157040 | PubMed |
| 9 | 33357454 | Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site. | Cancer Cell | 2021 | https://conductscience.org/library/papers/33357454 | PubMed |
| 10 | 11875500 | Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. | Nat Med | 2002 | https://conductscience.org/library/papers/11875500 | PubMed |
| 11 | 29576531 | Copper-Binding Small Molecule Induces Oxidative Stress and Cell-Cycle Arrest in Glioblastoma-Patient-Derived Cells. | Cell Chem Biol | 2018 | https://conductscience.org/library/papers/29576531 | PubMed |
| 12 | 27806324 | PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK. | Oncotarget | 2016 | https://conductscience.org/library/papers/27806324 | PubMed |
| 13 | 23360998 | Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53. | Nat Commun | 2013 | https://conductscience.org/library/papers/23360998 | PubMed |
| 14 | 15861488 | NMR investigation of hydrogen bonding and 1,3-tautomerism in 2-(2-hydroxy-5-substituted-aryl) benzimidazoles. | Magn Reson Chem | 2005 | https://conductscience.org/library/papers/15861488 | PubMed |
| 15 | 34862374 | Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ). | Nat Commun | 2021 | https://conductscience.org/library/papers/34862374 | PubMed |
| 16 | 23828940 | Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. | Science | 2013 | https://conductscience.org/library/papers/23828940 | PubMed |
| 17 | 29125602 | Mechanisms of transcriptional regulation by p53. | Cell Death Differ | 2018 | https://conductscience.org/library/papers/29125602 | PubMed |
| 18 | 19693097 | When mutants gain new powers: news from the mutant p53 field. | Nat Rev Cancer | 2009 | https://conductscience.org/library/papers/19693097 | PubMed |
| 19 | 22624712 | Allele-specific p53 mutant reactivation. | Cancer Cell | 2012 | https://conductscience.org/library/papers/22624712 | PubMed |
| 20 | 27533246 | Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status. | Oncotarget | 2016 | https://conductscience.org/library/papers/27533246 | PubMed |
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42598159 | Association between the expression of GSTP1 and mutant p53, poor chemotherapy response and metastasis in patients with osteosarcoma. | Oncol Lett | 2026 | https://conductscience.org/library/papers/42598159 | PubMed |
| 41279808 | Towards In Situ Dynamics of DNA-bound Full-Length p53 Tetramer. | bioRxiv | 2025 | https://conductscience.org/library/papers/41279808 | PubMed |
| 40729059 | Molecular Docking and Dynamic Studies of Chlorogenic Acid Isomers as Antagonists of p53 Transcription Factor for Potential Adjuvant Radiotherapy. | Asian Pac J Cancer Prev | 2025 | https://conductscience.org/library/papers/40729059 | PubMed |
| 40597785 | The complex journey of targeting RAS in oncology. | BMC Cancer | 2025 | https://conductscience.org/library/papers/40597785 | PubMed |
| 40116283 | Computational studies on the functional and structural impact of pathogenic mutations in enzymes. | Protein Sci | 2025 | https://conductscience.org/library/papers/40116283 | PubMed |
| 39930134 | Natural compound PEITC inhibits gain of function of p53 mutants in cancer cells by switching YAP-binding partners between p53 and p73. | Acta Pharmacol Sin | 2025 | https://conductscience.org/library/papers/39930134 | PubMed |
| 39450536 | TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review). | Int J Mol Med | 2025 | https://conductscience.org/library/papers/39450536 | PubMed |
| 39199355 | Pyrimidine Triones as Potential Activators of p53 Mutants. | Biomolecules | 2024 | https://conductscience.org/library/papers/39199355 | PubMed |
| 39185441 | A novel heuristic of rigid docking scores positively correlates with full-length nuclear receptor LRH-1 regulation. | Comput Struct Biotechnol J | 2024 | https://conductscience.org/library/papers/39185441 | PubMed |
| 38862470 | Structural basis of p53 inactivation by cavity-creating cancer mutations and its implications for the development of mutant p53 reactivators. | Cell Death Dis | 2024 | https://conductscience.org/library/papers/38862470 | PubMed |
| 38396641 | Most Monogenic Disorders Are Caused by Mutations Altering Protein Folding Free Energy. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38396641 | PubMed |
| 38358129 | Toward physics-based precision medicine: Exploiting protein dynamics to design new therapeutics and interpret variants. | Protein Sci | 2024 | https://conductscience.org/library/papers/38358129 | PubMed |
| 38018912 | Characterization on the oncogenic effect of the missense mutations of p53 via machine learning. | Brief Bioinform | 2023 | https://conductscience.org/library/papers/38018912 | PubMed |
| 37373306 | Identifying the Molecular Drivers of Pathogenic Aldehyde Dehydrogenase Missense Mutations in Cancer and Non-Cancer Diseases. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37373306 | PubMed |
| 36965249 | On the linkage of thermodynamics and pathogenicity. | Curr Opin Struct Biol | 2023 | https://conductscience.org/library/papers/36965249 | PubMed |
| 36964053 | Small-molecule correctors and stabilizers to target p53. | Trends Pharmacol Sci | 2023 | https://conductscience.org/library/papers/36964053 | PubMed |
| 36859359 | Targeting p53 pathways: mechanisms, structures, and advances in therapy. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/36859359 | PubMed |
Genes18
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35948006
GET https://conductscience.org/api/papers/v1/35948006/authors?page=2